Activation of Peripheral Blood CD3+ T-lymphocytes in Patients With Atrial Fibrillation
Activation of Peripheral Blood CD3+ T-lymphocytes in Patients With Atrial Fibrillation
复制标题
房颤患者外周血 CD3 T 淋巴细胞的激活
DOI：
10.1536/ihj.53.221
复制
发表时间：
2012-07-01
影响因子：
1.5
通讯作者：
Zheng, Qiangsun
中科院分区：
文献类型：
--
作者：
Liu, Li;Lee, Jun;Zheng, Qiangsun
心房颤动（AF）是一种常见疾病，其病理生理机制尚不清楚。越来越多的证据表明AF可能与免疫炎症反应有关，但外周血CD 3（+）T淋巴细胞的活化是否在AF的发病机制中起作用尚不清楚。50例阵发性房颤患者和56例持续性房颤患者接受了成功的电复律。应用流式细胞仪检测了51例正常人和51例患者外周血CD 69和HLA-DR阳性T淋巴细胞的百分率。患者组CD 69和HLA-DR水平高于健康对照组。随访3个月，复发组37例，窦性组50例。随访时窦性心律组患者的CD 69和HLA-DR水平均较复律前显著下调。然而，复发组在随访时和复律前的CD 69和HLA-DR水平之间无统计学显著差异。我们的研究结果表明，外周血CD 3（+）T淋巴细胞的活化与AF有关，并可能成为诊断或治疗的标志物。(Int Heart J 2012; 53：221-224）
Atrial fibrillation (AF) is a common disease with a poorly understood pathophysiological mechanism. Increasing evidence indicates that AF may be associated with immunologic inflammation responses, but it remains unclear whether activation of peripheral blood CD3(+) T-lymphocytes plays a role in the pathogenesis of AF. The aim of this study was to evaluate this phenomenon. Fifty paroxysmal AF patients and 56 persistent AF patients who underwent successful electrical cardioversion were enrolled. The percentages of CD69 and human leukocyte antigen DR (HLA-DR) positive peripheral blood CD3(+) T-lymphocytes, which indicate T-lymphocyte activation, were examined by flow cytometric analysis in the patients and 51 healthy controls. The patient groups had higher levels of CD69 and HLA-DR than the healthy controls. During the 3-month follow-up, 37 patients had recurrence of AF (recurrence group) and 50 patients remained in sinus (sinus group). The CD69 and HLA-DR levels in the sinus group were all significantly down-regulated at follow-up compared with before cardioversion. However, there were no statistically significant differences between the CD69 and HLA-DR levels in the recurrence group at follow-up and before cardioversion. Our findings suggest that activation of peripheral blood CD3(+) T-lymphocytes was associated with AF, and might be a diagnostic or therapeutic marker. (Int Heart J 2012; 53: 221-224)